Overview
EN ISO 11608-1:2022/A1:2026 is the latest amendment to the standard for needle-based injection systems (NIS) for medical use, specifically focusing on part 1: requirements and test methods. Published by CEN and developed through collaboration with ISO and technical committee ISO/TC 84, this amendment enhances the clarity and consistency of terminology and updates procedural details related to the testing and evaluation of injection systems. The amendment ensures alignment and precision across documentation, improving how manufacturers and stakeholders approach terminology, inspection, and performance verification for medical injection devices.
Key Topics
-
Terminology Consistency: Editorial inconsistencies are addressed, ensuring uniform use of terms such as “anticipated/normal conditions,” “in-use conditions,” “conditioning,” and “preconditioning.”
-
Primary Function Identification: Clarified guidelines require the identification of primary functions via assessment of design specifications, emphasizing dose delivery and accuracy.
-
Test Methods and Apparatus Requirements: Updated requirements for measurement systems specify accuracy, precision, repeatability, and reproducibility, particularly for high-precision test apparatus used in NIS evaluation.
-
Dosing Regions Procedures: Revised notes provide clearer guidance for dividing container contents for dosing evaluation, supporting more accurate system testing.
-
Test Case Matrix: The amendment summarizes required tests under different conditions and outlines the sequence for visual inspections and primary function assessments.
-
Verification Under Varying Conditions: The amendment strengthens requirements for conducting inspections and assessments both after stressed/challenge conditions and under normal/anticipated conditions.
-
Life-cycle and Functional Stability: Life-cycle testing now applies a defined safety factor, and “functional stability” encompasses both shelf-life and in-use life, underscoring the importance of system reliability from manufacture to disposal.
-
Risk and Harm Assessment: The amendment clarifies the distinction between evaluating essential performance based on both likelihood and severity of harm, and identifying primary functions based solely on severity.
Applications
This standard amendment is essential for:
-
Medical Device Manufacturers: Helps in the development and production of reliable, safe needle-based injection systems such as insulin pens, prefilled syringes, and auto-injectors. The clarified requirements improve the accuracy of design verification and validation processes.
-
Regulatory Compliance: Provides a harmonized reference for demonstrating conformity with European and international regulatory requirements, streamlining pathways for product approval and market access.
-
Quality Assurance and Testing Laboratories: Enables testing bodies to implement robust, reproducible, and compliant methods for product evaluation, ensuring consistent performance and safety over the product’s lifecycle.
-
Healthcare Providers and End-Users: Enhances confidence in the reliability and safety of injection systems, minimizing risks associated with dosing inaccuracies or device failure.
Related Standards
For a comprehensive approach to needle-based injection system safety and performance, consider the following related standards:
- ISO 11608 Series: Covers additional requirements for accessories, drug containers, pen-injectors, and more.
- EN ISO 23908: Focuses on sharps injury protection for medical devices.
- ISO 14971: Medical devices - Application of risk management to medical devices.
- ISO 10993 Series: Biocompatibility evaluation of medical device materials.
By adopting EN ISO 11608-1:2022/A1:2026, stakeholders support consistent terminology, thorough testing, and enhanced safety for needle-based injection systems, ensuring better protection for patients and healthcare professionals.